Ann: Increased Scheme Consideration from Pfizer, page-82

All -

a couple of things i have picked up on, but not yet seem to be covered:

Firstly - From the Ann today :-

On 30 May 2022, the Independent Expert provided a draft IER to the ResApp Board (Draft IER)
which determined that the value of a ResApp share (on a controlling interest basis) was A$0.146
to A$0.277, with a preferred value of A$0.207 per ResApp share.

The term 'on a controlling interest basis' appears to be vague, and somewhat outside the guidelines of the expert report - which should need to include future earnings etc. To me, the term 'on a controlling interest basis' implies what Pfizer are offering, and no more.

Secondly -

Pfizer have increased their offer on the non verification of covid data to 14.5 - meaning, that even though the Algos are showing gold standard, they are suggesting that - if its only a little bit above gold standard we want a discount. But it does indicate that they want the rest of the product anyway, and that the covid testing is only a 'would you like fries with that' add-on

The devil is in the detail here, and it appears to me that there are shenanigans afoot - and again, the BOD are assuming that most of us retail shareholders are nothing but stupid straw sucking donkey fiddlers.

Still 1m of Ports - a big NO